A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Psilocybin (Primary)
- Indications Depression; Major depressive disorder; Suicidal ideation
- Focus Therapeutic Use
- Acronyms P-TRD LTFU
- Sponsors COMPASS Pathways
Most Recent Events
- 18 Mar 2025 According to Compass Pathways media release, company announced the publication of results from the COMP004 study published in the March edition of the Journal of Clinical Psychiatry
- 21 Sep 2022 Status changed from recruiting to completed.
- 04 Sep 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database.